lucentis
novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmoloogilised vahendid - lucentis on näidustatud täiskasvanute jaoks:ravi neovascular (märg) vanusega seotud makuladegeneratsiooni (amd)raviks nägemispuudega tõttu choroidal neovascularisation (cnv)ravi nägemispuudega tõttu diabeediga macular turse (dme)ravi nägemispuudega tõttu macular turse teisejärguline võrkkesta veeni oklusioon (branch rvo-või kesk-rvo).
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmoloogilised vahendid - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloogilised vahendid - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloogilised vahendid - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
virbagen omega
virbac s.a. - kasside päritolu rekombinantne oomega interferoon - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. fiv-i nakatunud kassides oli suremus madal (5%) ja ravi ei mõjutanud.
dolpac 10 tablett
vetoquinol s.a. - prasikvanteel+oksanteel+püranteel - tablett - 50mg+200,28mg+49,94mg 6tk; 50mg+200,28mg+49,94mg 18tk; 50mg+200,28mg+49,94mg 30tk; 50mg+200,28mg+49,94mg 3tk
methotrexate ebewe 100 mg/ml infusioonilahuse kontsentraat
sandoz pharmaceuticals d.d. - metotreksaat - infusioonilahuse kontsentraat - 100mg 1ml 5ml 5tk; 100mg 1ml 10ml 1tk; 100mg 1ml 5ml 1tk; 100mg 1ml 50ml 5tk; 100mg 1ml 10ml 5tk
apovomin süstelahus
dechra regulatory b.v. - apomorfiin - süstelahus - 3mg 1ml 10ml 10tk; 3mg 1ml 10ml 1tk; 3mg 1ml 5ml 1tk; 3mg 1ml 20ml 1tk; 3mg 1ml 5ml 10tk
iopamiro süstelahus
bracco imaging s.p.a. - jopamidool - süstelahus - 612mg 1ml 30ml 1tk; 612mg 1ml 10ml 5tk; 612mg 1ml 200ml 1tk; 612mg 1ml 100ml 1tk; 612mg 1ml 50ml 1tk
dolpac 25 tablett
vetoquinol s.a. - prasikvanteel+oksanteel+püranteel - tablett - 125mg+500,7mg+124,85mg 18tk; 125mg+500,7mg+124,85mg 3tk; 125mg+500,7mg+124,85mg 60tk; 125mg+500,7mg+124,85mg 30tk